WO2019047654A1 - 一种取代苯乙酸衍生物的制备方法 - Google Patents

一种取代苯乙酸衍生物的制备方法 Download PDF

Info

Publication number
WO2019047654A1
WO2019047654A1 PCT/CN2018/099121 CN2018099121W WO2019047654A1 WO 2019047654 A1 WO2019047654 A1 WO 2019047654A1 CN 2018099121 W CN2018099121 W CN 2018099121W WO 2019047654 A1 WO2019047654 A1 WO 2019047654A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
reaction
substituted alkyl
low
Prior art date
Application number
PCT/CN2018/099121
Other languages
English (en)
French (fr)
Inventor
李洁平
高照波
柴兵
郑辉
刘声民
刘阿情
郭必豹
郑俊成
王长发
卢玮玮
Original Assignee
江苏瑞科医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏瑞科医药科技有限公司 filed Critical 江苏瑞科医药科技有限公司
Priority to EP18853433.3A priority Critical patent/EP3680227A4/en
Priority to JP2020535284A priority patent/JP7068467B2/ja
Priority to KR1020207006285A priority patent/KR102393122B1/ko
Priority to US16/644,205 priority patent/US20210078941A1/en
Publication of WO2019047654A1 publication Critical patent/WO2019047654A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/65—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by splitting-off hydrogen atoms or functional groups; by hydrogenolysis of functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/716—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/14—Preparation of carboxylic acid nitriles by reaction of cyanides with halogen-containing compounds with replacement of halogen atoms by cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/40—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C07C45/676—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton by elimination of carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/457—Saturated compounds containing a keto group being part of a ring containing halogen
    • C07C49/467—Saturated compounds containing a keto group being part of a ring containing halogen polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
    • C07C49/693—Unsaturated compounds containing a keto groups being part of a ring containing halogen polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/08—Preparation of carboxylic acids or their salts, halides or anhydrides from nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/377—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
    • C07C51/38—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups by decarboxylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/86—Unsaturated compounds containing keto groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Definitions

  • the invention belongs to the field of pharmaceutical synthesis, and relates to a preparation method of a substituted phenylacetic acid derivative, in particular to a preparation method of preparing 2-[4-(2-oxopentyl)phenylpropionic acid].
  • Loxoprofen is a class of non-steroidal anti-inflammatory propionic acid derivatives. This class of propionic acid derivatives also includes ibuprofen and naproxen. Loxoprofen is marketed in the form of sodium salt by Sankyo Corporation in Brazil, Mexico and Japan, Loxoprofen sodium, Japanese trade name Loxonin, Argentina under the trade name Oxeno, and India under the trade name Loxomac. It is suitable for oral administration in these countries, and its injectable preparation is approved for sale in Japan in January 2006.
  • the present invention provides a synthetic process for replacing a phenylacetic acid compound such as loxoprofen.
  • the synthesis process of the present invention enables the preparation of substituted phenylacetic acid compounds at low cost and in high yield.
  • the present invention provides novel compounds of formula G 1 G and the intermediate compound of formula the following structural formula:
  • R 1 is hydrogen or a low-substituted alkyl group
  • Z is a cyclopentanone group and a precursor thereof, the precursor form being Deion or metal reagent, or R 3 is a low substituted alkyl group
  • L 2 has the same definition as R 2 .
  • a second aspect of the present invention provides a method of preparing compounds of formula G and G type. 1, the disubstituted benzyl group cyclopentanone compound with a precursor form of a compound of formula or dihalo benzyl compounds prepared by reaction of the reaction equation below:
  • X is a halogen
  • L 1 is a halogen
  • OH, OMs, OTs, OTf, L 2 have the same definition as R 2 and are the same as defined above
  • Z is a cyclopentanone group and a precursor thereof, the precursor In the form Deion or metal reagent, or
  • the above disubstituted benzyl compound is prepared from a dihalobenzyl compound or a dibenzyl alcohol compound, and the reaction formula is as follows:
  • X is a halogen
  • R 3 is a low-substituted alkyl group
  • L 1 and L 2 are the same or different and are OMs, OTs, OTf, nitromethane, CN or carbon-carbon oxime bonds or
  • X is a halogen and R 3 is a low-substituted alkyl group.
  • a compound of Formula G Formula G. 1 and comprises a decarboxylation step in the preparation of compounds loxoprofen.
  • the order of the decarboxylation steps involved may be the first step, the second step or the third step, i.e., the order is variable. More preferably, the decarboxylation step precedes the cyanation reaction.
  • a compound of Formula G. 1 and comprises a step of cyclopentanone precursor form convert groups of cyclopentanone in the preparation of compounds loxoprofen.
  • the step sequence of converting the cyclopentanone group in the form of the precursor to cyclopentanone may be the first step, the second step or the third step.
  • R 1 is hydrogen or a low substituted alkyl group
  • R 3 is the same as described above.
  • the compound of the above formula III-1 is prepared by reacting 1,4-p-dihalobenzyl with an alkyl 2-oxocyclopentanecarboxylate, and the reaction formula is as follows:
  • X is a halogen, and in the formula, R 1 is hydrogen, and R 3 has the same meaning as defined above.
  • the above compound of the formula III-1' is prepared by reacting 1,4-p-dibenzyl alcohol with an alkyl 2-oxocyclopentanecarboxylate, and the reaction formula is as follows:
  • R 3 is the same as described above.
  • R 2 is another substituent which can be obtained by converting a compound of the formula III-1 and a compound of the formula III-1'.
  • 1,4-p-dibenzyl alcohol and 1,4-p-dihalobenzyl firstly prepared by a sulfonic acid esterification reaction, an amination reaction, a coupling reaction, etc., which are common in the art, or by a substitution reaction, or with a Grignard reagent After the reaction, it is further prepared by reacting with carbon dioxide.
  • the sulfonation reaction can be expressed as follows:
  • R 3 is the same as described above.
  • the compound of the above formula III-2 is prepared by cyanation of a compound of the formula III-1, and the reaction formula is as follows:
  • R 3 is the same as described above.
  • R 3 is the same as described above.
  • the compound of the above formula III-3 is prepared by alkylation of a compound of the formula III-2, and the reaction formula is as follows:
  • R 1 and R 3 are the same as described above.
  • the above three-step reaction such as the substitution reaction of 1 with an alkyl 2-oxocyclopentanecarboxylate, the 2 cyanation reaction, and the 3 alkylation reaction may be in any order in the reaction sequence.
  • 123 may be used as the above reaction equation, and the reaction sequence may also be 132, 321, or 213, and the reaction sequence may also be 231.
  • reaction formula is as follows:
  • R 1 and R 3 have the same meanings as defined above.
  • reaction sequence that is, the cyanation reaction is carried out first, then the alkylation reaction is carried out, and then reacted with the alkyl 2-oxocyclopentanecarboxylate, the reaction formula is expressed as follows:
  • R 1 and R 3 have the same meanings as defined above.
  • substitution reaction with the alkyl 2-oxocyclopentanecarboxylate of the present invention is carried out in the presence of a base such as potassium carbonate, sodium carbonate, sodium alkoxide or the like.
  • the cyanation reaction of the present invention uses a common cyanating agent such as sodium cyanide, potassium cyanide, cyanide or the like.
  • the alkylation reaction of the present invention uses a common alkylating agent such as dimethyl carbonate, dimethyl sulfate, trimethyl orthoformate or halomethane.
  • a common alkylating agent such as dimethyl carbonate, dimethyl sulfate, trimethyl orthoformate or halomethane.
  • the above reaction of the present invention can be carried out under the action of an organic solvent.
  • the organic solvent may be an organic solvent commonly used by those skilled in the art for substitution reaction, alkylation reaction, cyanation reaction, etc., such as DMF DMSO, NMP, 1,4-dioxane, methanol, ethanol, acetic acid. Ethyl ester, tetrahydrofuran, methyl tert-butyl ether or acetonitrile.
  • the intermediate compounds of the invention are useful in the preparation of loxoprofen. More preferably, the compound of formula III-3 is prepared by hydrolysis, and the reaction formula is as follows:
  • R 1 and R 3 have the same meanings as defined above, and when R 1 is a methyl group, it is loxoprofen.
  • the hydrolysis reagent used in the hydrolysis reaction is an acid commonly used in the art, and may be an organic acid or an inorganic acid such as sulfuric acid, hydrochloric acid or trifluoroacetic acid.
  • the invention uses a dihalobenzyl compound as a starting material, and obtains an intermediate compound of the formula III by a substitution reaction in any order, a cyanation reaction and an alkylation reaction.
  • R 1 is hydrogen or a low-substituted alkyl group
  • R 2 is a halogen or a cyano group
  • R 3 is a low-substituted alkyl group.
  • R 1 is a methyl group
  • R 2 is a cyano group
  • R 3 is a low-substituted alkyl group
  • a process for the preparation of a loxoprofen-type compound of the invention comprises the step of converting a cyclopentanone group to a cyclopentanone in the form of a precursor.
  • a cyclization reaction or the like well known in the art is employed.
  • the loxoprofen precursor form compound of the present invention is useful for the preparation of loxoprofen-like compounds.
  • the present invention also provides a preparation method of a loxoprofen compound by a substitution reaction, a decarboxylation reaction, a cyanation reaction and an alkylation reaction of a dihalobenzyl compound, and the specific reaction formula is as follows:
  • R 1 and R 3 have the same meanings as defined above.
  • the preparation method provided by the present invention has the following beneficial effects.
  • Second, the preparation process of the present invention is not taught by the prior art and is completely different from the use of the compound of U.S. Patent No. 568,1979.
  • the preparation method provided by the invention is suitable for industrial scale production and has certain economic benefits.
  • 1,4-p-Dichlorobenzyl (30 g, 0.17 mol), DMF (150 g, 4.74 vol) and sodium carbonate (19.8 g, 0.19 mol) were added to a 250 ml reaction flask, stirred uniformly, heated at 60 ° C, and added dropwise 2- Methyl oxocyclopentanecarboxylate (22.1 g, 0.16 mol) was added dropwise in about 1 hour. After the addition of the incubation reaction for 30 minutes, the temperature was lowered to 25 ° C, and the mother liquor was added with an appropriate amount of water to stir, and a solid precipitated.
  • a compound of formula III-1 (corresponding to R 1 is hydrogen, R 2 is chlorine, R 3 is methyl) (10 g, 0.036 mol), acetonitrile (50 g, 49.1 vol), sodium cyanide (1.9 g) is added to a 100 ml reaction flask. After the raw material disappeared, the mixture was cooled to room temperature (25 ° C), filtered, and concentrated under reduced pressure.
  • the compound of the formula III-2 (corresponding to R 1 being hydrogen, R 2 being a cyano group and R 3 being a methyl group) was obtained in an amount of 9.8 g, the content was 93.7%, and the yield was 94.7%.
  • a compound of formula III-2 (corresponding to R 1 being hydrogen, R 2 being cyano, R 3 being methyl) (30 g, 0.11 mol), dimethyl carbonate (24.8 g, 0.28 mol), was added to a 100 ml autoclave. Potassium carbonate (1.5 g, 0.011 mol), tetrabutylammonium bromide (1.8 g, 0.006 mol). The temperature was raised at 130-140 ° C, the autoclave pressure was about 0.3 MPa, and after continuous reaction for 10 hours, the temperature was lowered to 28 ° C, and a small amount of benzaldehyde was added dropwise to terminate the reaction.
  • a compound of formula III-3 (corresponding to R 1 is methyl, R 2 is cyano, R 3 is methyl) (18.5 g, 0.065 mol) and 80% sulfuric acid solution (16 g, 0.13 mol) is added to a 100 ml reaction flask. Start heating at 80-90 ° C, keep the reaction for 5 hours, start sampling and monitoring. When the raw materials disappear, start to cool to room temperature (25 ° C), extract with ethyl acetate, wash the organic layer with water, and concentrate to dryness under reduced pressure; Loxoprofen 16.4g, content 93.7%, yield 96.2%.
  • Insulation reaction 2.5-3.5 hours, start sampling and monitoring, when the raw materials disappear, start to cool down to 15-25 ° C, add tap water and ethyl acetate extraction, the organic layer is washed with 5% NaHCO 3 water, then washed with saturated NaCl, Finally, it was washed with tap water; the organic layer was concentrated to dryness under reduced pressure; 20.5 g of loxoprofen was obtained, the content was 93.7%, and the yield was 96.2%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明属于药物合成领域，涉及一种取代苯乙酸衍生物的制备方法，特别是涉及制备2-[4-(2-氧戊甲基)苯基丙酸]的制备方法。由二卤苄化合物或二取代苄基化合物，与环戊酮基或其前体形式化合物反应制备得到洛索洛芬的前体化合物(I)，其中，X为卤素，L1为卤素，OH，OMs，OTs，OTf，L2为卤素，氰基，羟基，-CH2OH，-CHO，硝基甲烷，酯基，-NR4R5，OTf，OTs，OMs，-C＝CR6，-C≡CR7，其中，R4，R5，R6，R7为低取代的烷基；Z为环戊酮基及其前体形式，所述前体形式为(II)，(III)，(IV)，(V)，或(VI)；R3为低取代的烷基。进一步的，包括将环戊酮基前体形式转换为环戊酮基的步骤，将洛索洛芬的前体化合物用于制备洛索洛芬类化合物。

Description

一种取代苯乙酸衍生物的制备方法
本申请要求于2017年9月7日提交中国专利局、申请号为201710800788.8、发明名称为“一种取代苯乙酸衍生物的制备方法”的中国专利申请的优先权，其全部内容通过引用结合在本申请中。
技术领域
本发明属于药物合成领域，涉及一种取代苯乙酸衍生物的制备方法，特别是涉及制备2-[4-(2-氧戊甲基)苯基丙酸]的制备方法。
背景技术
取代苯乙酸衍生物公开于美国专利中，例如US4161538中，结构式如下：
Figure PCTCN2018099121-appb-000001
在US4161538中，它们也被报导具备非常好的抗炎，止痛和退热活性效果。
当上述通式结构中A为氧，n的值为1，R 1为甲基时，一个非常有代表性的取代苯乙酸衍生物是洛索洛芬，具体结构式如下：
Figure PCTCN2018099121-appb-000002
洛索洛芬是非甾体抗炎丙酸衍生物一类药，这一类丙酸衍生物药其中还包括布洛芬和奈普生。洛索洛芬以钠盐的形式由Sankyo公司分别在巴西，墨西哥和日本上市，洛索洛芬钠，日本商品名为Loxonin，阿根廷商品名为Oxeno，印 度的商品名为Loxomac。在这些国家适于口服给药，它的注射给药制剂在日本于2006年1月获批准销售。
在美国专利US4161538，它公开了如下图示路线去合成洛索洛芬，其中n的值为1，R 1为甲基，
Figure PCTCN2018099121-appb-000003
在美国专利US5681979中，公开了如下结构的通式化合物，
Figure PCTCN2018099121-appb-000004
然而，这种通式化合物在该篇美国专利中并非用于制备洛索洛芬。
考虑到取代苯乙酸化合物洛索洛芬在医药领域的药物用途，有必要研究开发更多的适宜于洛索洛芬合成的工艺方法。
发明内容
本发明提供了取代苯乙酸化合物如洛索洛芬的合成工艺。本发明的合成工艺能够低成本，高收率的制备得到取代苯乙酸化合物。
首先，本发明提供了新的中间体化合物式G和式G 1化合物，结构式如下：
Figure PCTCN2018099121-appb-000005
其中，R 1为氢或低取代的烷基，R 2为卤素，氰基，OH，-CH 2OH，-CHO，硝基甲烷，酯基，-NR 4R 5，OTf，OTs，OMs，-C＝CR 6，-C≡CR 7，其中，R 4，R 5，R 6，R 7为低取代的烷基；Z为环戊酮基及其前体形式，所述前体形式为
Figure PCTCN2018099121-appb-000006
Figure PCTCN2018099121-appb-000007
离去基或金属试剂，
Figure PCTCN2018099121-appb-000008
或
Figure PCTCN2018099121-appb-000009
R 3为低取代的烷基；L 2的定义与R 2相同。
本发明第二方面提供了式G和式G 1化合物的制备方法，由二卤苄化合物或通式的二取代苄基化合物与环戊酮基的前体形式化合物反应制备得到，反应式如下：
Figure PCTCN2018099121-appb-000010
其中，X为卤素，L 1为卤素，OH，OMs，OTs，OTf，L 2的定义与R 2相同， 均与上述定义相同；Z为环戊酮基及其前体形式，所述前体形式为
Figure PCTCN2018099121-appb-000011
Figure PCTCN2018099121-appb-000012
离去基或金属试剂，
Figure PCTCN2018099121-appb-000013
或
Figure PCTCN2018099121-appb-000014
上述二取代苄基化合物由二卤苄化合物或二苄醇化合物制备，反应式如下：
Figure PCTCN2018099121-appb-000015
其中，X为卤素，R 3为低取代的烷基，L 1，L 2相同或不同的为OMs，OTs，OTf，硝基甲烷，CN或碳碳叁键或
Figure PCTCN2018099121-appb-000016
当L 2为
Figure PCTCN2018099121-appb-000017
时，反应式可如下表示：
Figure PCTCN2018099121-appb-000018
其中，X为卤素，R 3为低取代的烷基。
上述式G和式G 1化合物在制备洛索洛芬类化合物上包括了脱羧步骤。
所述包括的脱羧步骤的顺序可以为第一步，第二步或第三步，即是顺序可 变的。较优选地，脱羧步骤在氰化反应之前。
上述式G和式G 1化合物在制备洛索洛芬类化合物上包括了将前体形式的环戊酮基转换为环戊酮的步骤。所述包括的前体形式的环戊酮基转换为环戊酮的步骤顺序可以为第一步，第二步或第三步。
进一步本发明提供了式Ⅲ化合物，结构式如下：
Figure PCTCN2018099121-appb-000019
其中，R 1为氢或低取代的烷基，R 2为卤素，氰基，OH，-CH 2OH，-CHO，酯基，-NR 4R 5，OTf，OTs，OMs，-C＝CR 6，-C≡CR 7，其中，R 4，R 5，R 6，R 7为低取代的烷基；R 3为低取代的烷基。
当上述通式中R 1为氢，R 2为卤素时，该中间体化合物结构式如下：
Figure PCTCN2018099121-appb-000020
R 3的定义与上述相同。
上述式Ⅲ-1化合物由1,4-对二卤苄与2-氧代环戊烷羧酸烷基酯反应制备，反应式如下：
Figure PCTCN2018099121-appb-000021
其中，X为卤素，通式中R 1为氢，R 3的定义与上述相同。
当上述通式中R 1为氢，R 2为羟基时，该中间体化合物结构式如下：
Figure PCTCN2018099121-appb-000022
上述式Ⅲ-1’化合物由1,4-对二苄醇与2-氧代环戊烷羧酸烷基酯反应制备，反应式如下：
Figure PCTCN2018099121-appb-000023
R 3的定义与上述相同。
通式中R 2为其他取代基可以通过式Ⅲ-1化合物及式Ⅲ-1’化合物转换得到。或通过1,4-对二苄醇及1,4-对二卤苄先采用本领域常见的磺酸酯化反应，胺化反应，偶联反应等后经取代反应制备，或者与格氏试剂反应后进一步与二氧化碳反应制备。如磺酸酯化反应可用反应式表示如下：
Figure PCTCN2018099121-appb-000024
当上述通式中取代基R 2为氰基时,该中间体化合物结构式如下：
Figure PCTCN2018099121-appb-000025
其中，R 3的定义与上述相同。
上述式Ⅲ-2化合物由式Ⅲ-1化合物经氰化反应制备，反应式如下：
Figure PCTCN2018099121-appb-000026
其中，R 3的定义与上述相同。
当上述通式中取代基R 1为低取代的烷基，该中间体化合物结构式如下：
Figure PCTCN2018099121-appb-000027
R 3的定义与上述相同。
上述式Ⅲ-3化合物由式Ⅲ-2化合物经烷基化反应制备，反应式如下：
Figure PCTCN2018099121-appb-000028
其中，R 1，R 3的定义与上述相同。
另外，上述三步反应如①与2-氧代环戊烷羧酸烷基酯的取代反应，②氰化反应，③烷基化反应，在反应顺序上可以是任意顺序的。如可以为上述已经用反应方程式表示的①②③，反应顺序也可以为①③②，③②①或者②①③，反应顺序还可以为②③①。
当反应顺序为③②①时，反应式如下：
Figure PCTCN2018099121-appb-000029
其中，X为卤素，R 1，R 3的定义与上述相同。
当反应顺序为②③①即先进行氰化反应，然后进行烷基化反应，再与2-氧代环戊烷羧酸烷基酯反应时，反应式表示如下：
Figure PCTCN2018099121-appb-000030
其中，X为卤素，R 1，R 3的定义与上述相同。
本发明所述与2-氧代环戊烷羧酸烷基酯的取代反应，在碱存在的条件下进行，所述碱为碳酸钾，碳酸钠，醇钠等。
本发明的氰化反应使用常见的氰化试剂，如***，***，氰化酮等。
本发明的烷基化反应使用常见的烷基化试剂，如碳酸二甲酯，硫酸二甲酯，原甲酸三甲酯或卤甲烷等。
本发明上述反应可以在有机溶剂的作用下进行。所述有机溶剂可以为本领域技术人员常用的用于取代反应，烷基化反应，氰化反应等的有机溶剂，如DMF DMSO、NMP、1,4-二氧六环、甲醇、乙醇、乙酸乙酯、四氢呋喃、甲基叔丁基醚或乙腈等。
本发明的中间体化合物用于制备洛索洛芬。较优选地为，式Ⅲ-3化合物经水解反应制备，反应式表示如下：
Figure PCTCN2018099121-appb-000031
R 1，R 3的定义与上述相同，当R 1为甲基时，即为洛索洛芬。
所述水解反应使用的水解试剂为本领域常用的酸，可以为有机酸或无机酸，如硫酸、盐酸或三氟乙酸等。
本发明使用二卤苄化合物作为起始原料，经任意顺序的取代反应，氰化反应和烷基化反应制备得到中间体式Ⅲ化合物，
Figure PCTCN2018099121-appb-000032
其中，R 1为氢或低取代的烷基，R 2为卤素或氰基，R 3为低取代的烷基。
当R 1为甲基，R 2为氰基，R 3为低取代的烷基时，上述式Ⅲ-3化合物经水解反应即可制备得到洛索洛芬。
本发明洛索洛芬类化合物的制备方法，包括前体形式的环戊酮基转换为环戊酮的步骤。如采用本领域熟知的环合反应等。本发明的洛索洛芬前体形式化合物用于制备洛索洛芬类化合物。
另一方面，本发明还提供了一种由二卤苄化合物经取代反应、脱羧反应、氰化反应和烷基化反应制备得到洛索洛芬类化合物的制备方法，具体的反应式如下：
Figure PCTCN2018099121-appb-000033
其中，X为卤素，R 1，R 3的定义与上述相同。
本发明提供的制备方法有下述有益效果。首先，提供了制备取代苯乙酸衍生物的替代方案。第二，本发明的制备方法没有被现有技术所教导，与美国专利US5681979的化合物用途完全不同。第三，在反应过程中，使用二卤苄化合物作为起始原料，价格便宜且方便获得。第四，本发明提供的制备方法适合工业化规模生产并具备一定的经济效益。
具体实施方式
实施例1：
Figure PCTCN2018099121-appb-000034
在250ml反应瓶中加入1,4-对二氯苄(30g，0.17mol)，DMF(150g，4.74vol)和碳酸钠(19.8g，0.19mol)，搅拌均匀、升温60℃，滴加2-氧代环戊烷羧酸甲酯(22.1g，0.16mol)，大约1小时左右滴完，加完保温反应30分钟后，降温到25℃抽滤、母液加入适量水搅拌，有固体析出。抽滤、母液用乙酸乙酯萃取，减压浓缩干，得到式Ⅲ-1化合物(对应R 1为氢，R 2为氯，R 3为甲基)47.0g，含量77.3％，收率83.3％。
实施例2：
Figure PCTCN2018099121-appb-000035
在100ml反应瓶中加入式Ⅲ-1化合物(对应R 1为氢，R 2为氯，R 3为甲基)(10g，0.036mol)，乙腈(50g，49.1vol)，***(1.9g，0.039mol)，升温回流反应，原料消失后，降到室温(25℃)，抽滤、减压浓缩干后，加入乙酸乙酯和水搅拌分层、有机层减压浓缩干。得到式Ⅲ-2化合物(对应R 1为氢，R 2为氰基，R 3为甲基)9.8g，含量93.7％，收率94.7％。
实施例3：
Figure PCTCN2018099121-appb-000036
在100ml高压反应釜中加入式Ⅲ-2化合物(对应R 1为氢，R 2为氰基，R 3为甲基)(30g，0.11mol)，碳酸二甲酯(24.8g，0.28mol)，碳酸钾(1.5g，0.011mol)，四丁基溴化铵(1.8g，0.006mol)。开始升温130-140℃反应，高压釜压力大约0.3Mpa，连续反应10小时后，降温到28℃，滴加少量苯甲醛终止反应。抽滤、少量乙酸乙酯淋洗，用1N的稀盐酸洗涤，再用水洗涤。有机层减压浓缩干，得到式Ⅲ-3化合物(对应R 1为甲基，R 2为氰基，R 3为甲基)32.6g，含量78.1％，收率80.5％。
实施例4：
Figure PCTCN2018099121-appb-000037
在100ml反应瓶中加入式Ⅲ-3化合物(对应R 1为甲基，R 2为氰基，R 3为甲基)(18.5g，0.065mol)和加入80％的硫酸溶液(16g，0.13mol)，开始加热80-90℃， 保温反应5小时，开始取样监测，当原料消失后，开始降温到室温(25℃)，加入乙酸乙酯萃取，有机层用水洗后，减压浓缩干；得到洛索洛芬16.4g，含量93.7％，收率96.2％。
实施例5：
Figure PCTCN2018099121-appb-000038
在100ml反应瓶中加入式Ⅲ-1化合物(对应X为氯，R 3为甲基)(21g，0.075mol)、冰乙酸(37ml，2vol)和35％的浓盐酸(63ml，3vol)，开始加热90-95℃，保温反应2.5-3.5小时，开始取样监测，当原料消失后，开始降温到15-25℃，加入自来水和乙酸乙酯萃取，有机层先用5％的NaHCO 3水洗，再用饱和NaCl洗，最后用自来水洗；有机层减压浓缩干；得到式Ⅳ化合物(对应X为氯)19.7g，含量81.4％，收率96.1％。
实施例6：
Figure PCTCN2018099121-appb-000039
在100ml反应瓶中加入式Ⅳ化合物(对应X为氯)(10g，0.045mol)，乙腈(50g，5vol)，***(2.4g，0.049mol)，升温回流反应，原料消失后，降到室温(25℃)，抽滤、减压浓缩干后，加入乙酸乙酯和水搅拌分层、有机层用饱和NaCl洗，再用自来水洗；减压浓缩干。得到式Ⅴ化合物9.68g，含量93.7％，收率94.7％。
实施例7：
Figure PCTCN2018099121-appb-000040
在100ml高压反应釜中加入式Ⅴ化合物(30g，0.14mol)，碳酸二甲酯(31.5g， 0.35mol)，碳酸钾(1.5g，0.011mol)，四丁基溴化铵(1.8g，0.006mol)。开始升温130-140℃反应，高压釜压力大约0.3Mpa，连续反应10小时后，降温到28℃，滴加少量苯甲醛终止反应。抽滤、少量乙酸乙酯淋洗，用1N的稀盐酸洗涤，再用自来水洗涤；有机层减压浓缩干，得到式Ⅵ化合物(对应R 1为氢)31.7g，含量81.1％，收率80.4％。
实施例8：
Figure PCTCN2018099121-appb-000041
在100ml反应瓶中加入式Ⅵ化合物(对应R 1为氢)(18.5g，0.081mol)、冰乙酸(37ml，2vol)和35％的浓盐酸(55.5ml，3vol)，开始加热90-95℃，保温反应2.5-3.5小时，开始取样监测，当原料消失后，开始降温到15-25℃，加入自来水和乙酸乙酯萃取，有机层先用5％的NaHCO 3水洗，再用饱和NaCl洗，最后用自来水洗；有机层减压浓缩干；得到洛索洛芬20.5g，含量93.7％，收率96.2％。

Claims (14)

  1. 一种式G和式G 1化合物，结构式如下：
    Figure PCTCN2018099121-appb-100001
    其中，R 1为氢或低取代的烷基，R 2为卤素，氰基，羟基，-CH 2OH，-CHO，硝基甲烷，酯基，-NR 4R 5，OTf，OTs，OMs，-C＝CR 6，-C≡CR 7，其中，R 4，R 5，R 6，R 7为低取代的烷基；Z为环戊酮基及其前体形式，所述前体形式为
    Figure PCTCN2018099121-appb-100002
    Figure PCTCN2018099121-appb-100003
    R 3为低取代的烷基；L 2的定义与R 2相同。
  2. 一种式Ⅲ化合物，结构式如下：
    Figure PCTCN2018099121-appb-100004
    其中，R 1为氢或低取代的烷基，R 2为卤素，氰基，羟基，-CH 2OH，-CHO，硝基甲烷，酯基，-NR 4R 5，OTf，OTs，OMs，-C＝CR 6，-C≡CR 7，其中，R 4，R 5，R 6，R 7为低取代的烷基；R 3为低取代的烷基。
  3. 权利要求2中的化合物，结构式如下：
    Figure PCTCN2018099121-appb-100005
    其中，X为卤素，R 1，R 3为低取代的烷基。
  4. 权利要求1中式G和式G 1化合物的制备方法，其特征在于，由二卤苄化合物或通式的二取代苄基化合物与环戊酮基的前体形式化合物反应制备得到，反应式如下：
    Figure PCTCN2018099121-appb-100006
    其中，X为卤素，L 1为卤素，OH，OMs，OTs，OTf，L 2的定义与R 2在权利要求1中的定义相同；Z的定义与权利要求1中的相同。
  5. 根据权利要求4所述的制备方法，其特征在于，所述二取代苄基化合物由二卤苄化合物或二苄醇化合物制备，反应式如下：
    Figure PCTCN2018099121-appb-100007
    Figure PCTCN2018099121-appb-100008
    其中，X为卤素，R 3为低取代的烷基，L 1，L 2相同或不同的为OMs，OTs，OTf，硝基甲烷，-CN或碳碳叁键或
    Figure PCTCN2018099121-appb-100009
  6. 权利要求1中的式G和式G 1化合物，其特征在于，在制备洛索洛芬类化合物上包括了脱羧步骤。
  7. 根据权利要求6所述的制备方法，其特征在于，所述包括的脱羧步骤的顺序为第一步，第二步或第三步。
  8. 一种权利要求3中式Ⅲ-1化合物的制备方法，其特征在于，1,4-对二卤苄与2-氧代环戊烷羧酸烷基酯反应制备，反应式如下：
    Figure PCTCN2018099121-appb-100010
    其中，X为卤素，R 3为低取代的烷基。
  9. 一种权利要求3中式Ⅲ-2化合物的制备方法，其特征在于，由式Ⅲ-1化合物经氰化反应制备，反应式如下：
    Figure PCTCN2018099121-appb-100011
    其中，X为卤素，R 3为低取代的烷基。
  10. 一种权利要求3中式Ⅲ-3化合物的制备方法，其特征在于，由式Ⅲ-2化合物经烷基化反应制备，反应式如下：
    Figure PCTCN2018099121-appb-100012
    其中，R 1，R 3为低取代的烷基。
  11. 一种权利要求3中式Ⅲ-3化合物的制备方法，其特征在于，经任意顺序的取代反应，氰化反应和烷基化反应制备得到，反应式如下：
    Figure PCTCN2018099121-appb-100013
    其中，X为卤素，R 1，R 3为低取代的烷基。
  12. 权利要求3中式Ⅲ-3化合物的用途，其特征在于，进一步经脱羧反应和水解反应制备洛索洛芬类化合物，
    Figure PCTCN2018099121-appb-100014
    其中，R 1为低取代的烷基。
  13. 权利要求1中式G和式G 1化合物的用途，其特征在于，进一步包括将前体形式的环戊酮基转换为环戊酮的步骤制备洛索洛芬类化合物。
  14. 一种洛索洛芬类化合物的制备方法，其特征在于，经取代反应、脱羧反应、氰化反应、烷基化反应和水解反应制备得到，反应式如下：
    Figure PCTCN2018099121-appb-100015
    其中，X为卤素，R 1，R 3为低取代的烷基。
PCT/CN2018/099121 2017-09-07 2018-08-07 一种取代苯乙酸衍生物的制备方法 WO2019047654A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP18853433.3A EP3680227A4 (en) 2017-09-07 2018-08-07 PROCESS FOR THE PREPARATION OF A SUBSTITUTED PHENYLACETIC ACID DERIVATIVE
JP2020535284A JP7068467B2 (ja) 2017-09-07 2018-08-07 置換フェニル酢酸誘導体の製造方法
KR1020207006285A KR102393122B1 (ko) 2017-09-07 2018-08-07 치환된 페닐아세트산 유도체의 제조방법
US16/644,205 US20210078941A1 (en) 2017-09-07 2018-08-07 Method For Preparing Substituted Phenylacetic Acid Derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710800788.8A CN109467506B (zh) 2017-09-07 2017-09-07 一种取代苯乙酸衍生物的制备方法
CN201710800788.8 2017-09-07

Publications (1)

Publication Number Publication Date
WO2019047654A1 true WO2019047654A1 (zh) 2019-03-14

Family

ID=65633472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/099121 WO2019047654A1 (zh) 2017-09-07 2018-08-07 一种取代苯乙酸衍生物的制备方法

Country Status (6)

Country Link
US (1) US20210078941A1 (zh)
EP (1) EP3680227A4 (zh)
JP (1) JP7068467B2 (zh)
KR (1) KR102393122B1 (zh)
CN (1) CN109467506B (zh)
WO (1) WO2019047654A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109553518B (zh) * 2017-09-27 2021-12-07 江苏瑞科医药科技有限公司 一种取代苯乙酸衍生物的制备方法
CN117203189A (zh) * 2021-04-14 2023-12-08 株式会社Lg化学 制备用于合成鞘氨醇-1-磷酸酯受体激动剂的中间体的方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161538A (en) 1977-04-05 1979-07-17 Sankyo Company Limited Substituted phenylacetic acid derivatives and process for the preparation thereof
US5681979A (en) 1995-03-10 1997-10-28 Kureha Kagaku Kogyo Kabushiki Kaisha Process for the producing of alkylcyclopentanone derivatives
JP2000327603A (ja) * 1999-05-20 2000-11-28 Ohara Yakuhin Kogyo Kk プロピオン酸誘導体の製造方法
CN101412670A (zh) * 2007-10-19 2009-04-22 浙江普洛医药科技有限公司 洛索洛芬钠的合成方法
CN104326903A (zh) * 2014-10-14 2015-02-04 合肥远志医药科技开发有限公司 一种高纯度洛索洛芬钠二水合物的工业化生产方法
CN104710309A (zh) * 2015-02-05 2015-06-17 浙江普洛医药科技有限公司 洛索洛芬钠及其中间体的合成方法
CN105017009A (zh) * 2015-06-29 2015-11-04 千辉药业（安徽）有限责任公司 一种洛索洛芬钠的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN106316837B (zh) * 2015-06-24 2020-04-24 浙江九洲药业股份有限公司 一种取代苯乙酸衍生物的制备方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161538A (en) 1977-04-05 1979-07-17 Sankyo Company Limited Substituted phenylacetic acid derivatives and process for the preparation thereof
US5681979A (en) 1995-03-10 1997-10-28 Kureha Kagaku Kogyo Kabushiki Kaisha Process for the producing of alkylcyclopentanone derivatives
JP2000327603A (ja) * 1999-05-20 2000-11-28 Ohara Yakuhin Kogyo Kk プロピオン酸誘導体の製造方法
CN101412670A (zh) * 2007-10-19 2009-04-22 浙江普洛医药科技有限公司 洛索洛芬钠的合成方法
CN104326903A (zh) * 2014-10-14 2015-02-04 合肥远志医药科技开发有限公司 一种高纯度洛索洛芬钠二水合物的工业化生产方法
CN104710309A (zh) * 2015-02-05 2015-06-17 浙江普洛医药科技有限公司 洛索洛芬钠及其中间体的合成方法
CN105017009A (zh) * 2015-06-29 2015-11-04 千辉药业（安徽）有限责任公司 一种洛索洛芬钠的合成方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE Registry 30 November 2006 (2006-11-30), Database accession no. 914358-39-7 *
See also references of EP3680227A4

Also Published As

Publication number Publication date
KR102393122B1 (ko) 2022-05-02
JP7068467B2 (ja) 2022-05-16
EP3680227A1 (en) 2020-07-15
US20210078941A1 (en) 2021-03-18
CN109467506B (zh) 2021-12-07
EP3680227A4 (en) 2021-06-02
KR20200035109A (ko) 2020-04-01
JP2020532593A (ja) 2020-11-12
CN109467506A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
CN110183392B (zh) 一种3-取代苯基-4，5-二氢异噁唑衍生物的制备方法及其用途和中间体
CA2723878C (en) Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
CA2769960C (en) Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
WO2019047654A1 (zh) 一种取代苯乙酸衍生物的制备方法
CN109553518B (zh) 一种取代苯乙酸衍生物的制备方法
CN105884626B (zh) 一种2‑氨基茚满衍生物的合成方法及其产品
JP2682705B2 (ja) ２，６−ジクロロフェニルアミノベンゼン酢酸誘導体及びジフェニルアミン誘導体の製造方法。
CN102267934B (zh) 一种6-甲氧羰基吲哚酮的制备方法
US3362988A (en) Alkanoylnaphthyloxy-carboxylic acids
CN106316837B (zh) 一种取代苯乙酸衍生物的制备方法
WO2018228149A1 (zh) 一种取代苯乙酸衍生物的制备方法
WO2019161705A1 (zh) 一种1，6-(对脒基苯基)己二醚新的合成方法
CN110903245B (zh) 一种合成1-烷基-2-三氟甲基-5-氨基-1h-咪唑的关键中间体及其制备方法
KR100836528B1 (ko) 이토프리드 염산염의 제조방법
EP1082290A1 (en) Process for the preparation of aceclofenac
CN110885296B (zh) 一种溴芬酸钠的制备方法
WO2008032546A1 (fr) PROCÉDÉ DE PRODUCTION D'ESTER DE BENZYLE D'α-AMINOACIDE OPTIQUEMENT ACTIF
JP5008796B2 (ja) 芳香族カルボン酸の製造方法
JPS6261982A (ja) コタルニンの製造方法
CN107935909A (zh) 一种尼达尼布（nintedanib）及其中间体的合成方法
WO2022222473A1 (zh) 阿哌沙班的中间体及制备方法
JP4254093B2 (ja) ５−ハロゲノインドールの製法
WO2020042841A1 (zh) 一种(1r,3s)-3-氨基-1-环戊醇及其盐的制备方法
Weizmann et al. ATTEMPTED SYNTHESIS OF HEMIPINIC ACID FROM GUAIACOL
JPS5942375A (ja) ４−ヒドロキシ−２−チオフエン酢酸誘導体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18853433

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20207006285

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020535284

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018853433

Country of ref document: EP

Effective date: 20200407